clinical_trial-web

Tesaro’s ovarian cancer drug success threatens market rivals

October 12, 2016
Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib

Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …

Gamida Cell receives Breakthrough Therapy Designation from FDA

October 12, 2016
Research and Development Breakthrough Therapy Designation, FDA, Gamida Cell, leukaemia, lymphoma

Gamida Cell have been granted a Breakthrough Therapy Designation for their NiCord drug. NiCord has already passed through Phase I …

transgene

Transgene announce key partnership with Merck KGaA and Pfizer

October 12, 2016
Research and Development Cancer, France, Merck Group, Pfizer, Transgene, avelumab, head, neck

Transgene, a company that designs and developed targeted immunotherapies to treat cancer and infectious diseases, has announced a collaboration agreement …

NICE backs Celgene’s Otezla for psoriatic arthritis

October 12, 2016
Research and Development, Sales and Marketing Celgene, NICE, otezla

The national Institute of Health and Care Excellence has issued recommendation of Celgene’s Otezla (apremilast) for the treatment of psoriatic …

astrazeneca_logo_building

AstraZeneca forced to abandon Phase II trial

October 12, 2016
Research and Development AstraZeneca, Synairgen, asthma, cold, common cold

Synairgen, a respiratory drug discovery and development company, has developed a drug, AZD9412, alongside AstraZeneca to treat and prevent severe …

aaeaaqaaaaaaaaiyaaaajgqxy2rmmzrlltrhmzktndzhns05mza3lwmwmjliywjmzdu5zg

Sanofi appoint Alan Main to Executive Committee and Executive Vice President Consumer Healthcare

October 11, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Sanofi announced the appointment of Alan Main as Executive Vice President Consumer Healthcare effective October 1.Mr Main, who previously worked …

exelixis_hq_web

Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial

October 11, 2016
Manufacturing and Production, Research and Development Cabometyx, Exelixis, Pfizer, Phase II, Sutent, advanced renal cell carcinoma

Phase II results presented by genomics-based discovery company  Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …

nordicnanovector_final_logo

Nordic Nanovector and LegoChem Biosciences enter into collaboration

October 11, 2016
Manufacturing and Production

The Norwegian company Nordic Nanovector and the South Korean company LegoChem Biosciences have begun a collaboration to develop novel CD37-targeting …

takeda_world

Takeda enters $790m cancer development deal

October 11, 2016
Manufacturing and Production, Research and Development Cancer, Crescendo Biologics, Takeda, clinical partnership, humabody

Takeda and Crescendo Biologics have shaken hands on a $790 million deal to develop and commercialise cancer therapeutics using Crescendo’s …

Roche granted further good news by FDA

October 11, 2016
Manufacturing and Production Actembra, Alecensa, FDA, Lucentis, Roche, United States, america

Roche was given further good news by FDA after receiving a Priority Review for its Lucentis drug – this news …

teva-kim-innes-250

New UK & Ireland general manager for Teva

October 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, appointment

Kim Innes has been appointed by Teva as its new general manager of UK & Ireland. Innes succeeds Richard Daniell, …

flag_of_the_united_arab_emirates

UAE’s pharmaceutical market projected to grow from $3 billion to $5.7 billion by 2020

October 10, 2016
Manufacturing and Production Abu Dhabi, Dubai, GlobalData, United Arab Emires, growth, medical tourism, pharmaceutical market

United Arab Emirates’ pharmaceutical market is set for growth of 13% annually to reach $5.7 billion by 2020, up from …

shutterstock_142740349_resize_3

Educating pharma

October 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing educated, funding, medical education, transparency

Originally published in the October issue of Pharmafocus, Sean Murray takes a look at how pharma continues to occupy a key …

opdivo_1_1

Failure for BMS’ Opdivo in lung cancer trial

October 10, 2016
Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq

Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …

roche__tree

Roche’s lung cancer success spells competition for BMS’ Opdivo

October 10, 2016
Research and Development, Sales and Marketing BMS, Roche, lung cancer, opdivo, tecentriq

Roche’s immune-system booster drug Tecentriq (atezolizumab) may cause trouble in the lung cancer field for leader Bristol-Myers Squibb’s Opdivo according …

msd_merck_night_building

MSD’s Keytruda twice as successful against standard therapy for lung cancer

October 10, 2016
Sales and Marketing Bristol-Myers Squibb, MSD, Merck, keytruda

MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient …

1280px-epi-pen_1

Mylan agrees $465m settlement over EpiPen misclassification

October 10, 2016
Business Services, Medical Communications, Sales and Marketing Heather Bresch, Mylan, Price hike, epipen

In the latest scandal in the EpiPen price hike saga, the US Department of Justice has made claims that the …

novartis_building

Novartis’ new drug muscles in on Pfizer’s territory

October 10, 2016
Sales and Marketing Eli Lilly, Novartis, Pfizer, ibrance, ribociclib

A drug developed by Novartis, ribociclib, when combined with an older drug, letrozole, has been shown to reduce risk of progression …

NICE recommends Forxiga in Triple Therapy for Diabetes

October 7, 2016
Medical Communications AstraZeneca, Forxiga, NHS, NICE, diabetes, type 2 diabetes

The news of NICE’s approval of the Forxiga comes in a busy week for AstraZeneca. They have sold three drugs, …

The Gateway to Local Adoption Series

Latest content